Schie, L.M. van (2013) Expression of Estrogen Receptor Alpha and Beta in Prostate Cancer and Metastases. thesis, Medicine.
Full text available on request.Abstract
Background: Imaging has become an essential part in treatment selection and treatment planning in local and advanced prostate cancer. However, current imaging modalities are not sensitive enough to detect different stages of prostate cancer. 18F-FES is a radiotracer targeted against estrogen receptor alpha and beta (ERα and ERβ), which can be of use as imaging target in prostate cancer. Objective: The first aim was to determine whether an expression difference of ERα and ERβ in normal prostate and prostate cancer exists. The second aim was to determine whether there is expression of ERα and ERβ in prostate cancer metastases. Material and Methods: 32 patients samples with metastatic prostate cancer and 18 controls were included. These patients underwent prostate biopsies, (cysto)prostatectomy and/or a pelvic lymph node dissection in the period of 01-01-1997 to 19-03-2012. An immunohistochemical study was performed. All the available tissue of 18 control, 31 prostate cancer, 55 lymph node and 3 bone samples were stained for ERα and ERβ. Results: Both ERα and ERβ were found in benign and malignant tissue. ERα expression was most often seen in stromal cells and controls showed the highest expression. Expression of ERβ was more often positive compared to ERα and was seen in epithelial nuclei, cytoplasm and stromal cells. Comparing normal prostate with prostate cancer showed an ERβ expression of 89% and 94% in epithelial nuclei with a median Allred score of 4 and 8, respectively. ERα and ERβ immunoreactivity was observed in lymph node metastases in 44% and 85% of the epithelial nuclei, with a median Allred score of 2 and 4, respectively. Conclusions: No significant difference was observed between normal prostate and prostate cancer. These results suggest that 18F-FES is not an interesting candidate for staging of the primary tumour of prostate cancer. However, expression of ERβ in metastases makes 18F-FES suitable for measuring treatment response or follow-up of recurrent disease.
| Item Type: | Thesis (Thesis) |
|---|---|
| Supervisor name: | JONG, I.J. DE MD and HOVING, H.D. MD and DEPARTMENT OF UROLOGY and UNIVERITY MEDICAL CENTER GRONINGEN |
| Faculty: | Medical Sciences |
| Date Deposited: | 25 Jun 2020 11:01 |
| Last Modified: | 25 Jun 2020 11:01 |
| URI: | https://umcg.studenttheses.ub.rug.nl/id/eprint/2123 |
Actions (login required)
 |
View Item |